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I. Background
Acute myocardial infarction (AMI) is a catastrophic manifes-
tation of coronary artery disease that strikes more than
900 000 Americans each year. One fourth of afflicted patients
die, and many survivors develop impaired functional status,
anginal symptoms, and diminished quality of life. Fortu-
nately, an explosion in scientific discovery and clinical
research has created great potential for treating patients, and
concurrent with these advances, there has been a marked
decrease in AMI mortality (1). Yet the full benefit of
scientific progress is often unrealized by patients because of
the gap between knowledge and its application to clinical
care.
To address this gap, the AMI Working Group of the first
American Heart Association (AHA)/American College of
Cardiology (ACC) Scientific Forum on Quality of Care and
Outcomes Research in Cardiovascular Disease and Stroke
brought together national leaders and committed practitioners
to share knowledge and insights on measuring and improving
the quality of AMI care (see Acknowledgments for Working
Group members). This group sought to create a comprehen-
sive framework for quantifying the components of AMI care
and to summarize current methodological considerations in
quality assessment/improvement while formulating a re-
search agenda to address unmet needs in the field. The
present report supplements the overall insights gained from
the conference (2) with data specifically relevant to the
quantification of care for AMI patients. Although new evi-
dence may alter the relevance of specific measures, it is
hoped that the principles described in this report will assist
local and national organizations in their efforts to improve the
quality of care for patients with AMI.
II. Conceptualizing Quality in the Treatment
of AMI
As a means of conceptualizing the components of quality
assessment, the Working Group on AMI embraced the
approach of Donabedian (3), which considers 3 domains of
quality: structure, process, and outcome. Structure refers to
those aspects of care that exist independently of the patient.
Examples include provider training and experience, availabil-
ity of specialized treatments, nurse-to-patient ratios, treat-
ment and discharge plans, and procedures to facilitate the
rapid triage of AMI patients in the emergency department.
Process refers to those actions performed in delivering care to
patients and includes such concepts as the medications given
and timing of their administration, the use of diagnostic and
therapeutic procedures, and patient counseling. Outcomes are
the events that occur as a result of the disease process and/or
care provided. Examples include further progression of the
disease (mortality, infarct extension, development of conges-
tive heart failure, treatment complications), health status
(subsequent functioning, symptoms, and quality of life),
costs, and patient satisfaction (Figure 1).
“Challenges and Opportunities in Quantifying the Quality of Care for Acute Myocardial Infarction: Summary From the Acute Myocardial Infarction
Working Group of the American Heart Association/American College of Cardiology First Scientific Forum on Quality of Care and Outcomes Research
in Cardiovascular Disease and Stroke” is an American Heart Association/American College of Cardiology Conference Proceedings statement. The
recommendations set forth in this report are those of the conference participants and do not necessarily reflect the official position of the American Heart
Association or the American College of Cardiology Foundation.
The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside
relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required
to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.
This statement has been co-published in the April 1, 2003, issue of Circulation.
This statement was approved by the American Heart Association Science Advisory and Coordinating Committee on January 31, 2003. A single reprint
is available by calling 800-242-8721 (US only) or writing the American Heart Association, Public Information, 7272 Greenville Ave, Dallas, TX
75231-4596. Ask for reprint No. 71-0255. To purchase additional reprints: up to 999 copies, call 800-611-6083 (US only) or fax 413-665-2671; 1000
or more copies, call 410-528-4426, fax 410-528-4264, or e-mail klbradle@lww.com. To make photocopies for personal or educational use, call the
Copyright Clearance Center, 978-750-8400.
(J Am Coll Cardiol 2003;41:1653–63.)
©2003 by the American Heart Association, Inc.
doi: 10.1016/S0735-1097(03)00415-7
AHA/ACC Conference Proceedings
III. Principles for the Selection of Quality
Performance Measures
Performance measures are the discrete parameters for struc-
ture, process, or outcome, the attainment of which defines
good quality care. Although new knowledge will necessitate
changing specific measures over time, certain principles can
facilitate the evaluation of proposed performance measures.
Important attributes for performance measurements include:
(1) The performance measure must be meaningful. Any
potential performance measure must either be a mean-
ingful outcome to patients or have a close linkage to
such an outcome.
(2) The measure must be valid and reliable. To success-
fully quantify healthcare quality, it must be possible to
reliably and accurately measure the structure, process,
or outcome of interest.
(3) The measure can account for patient variability. Al-
though more relevant to process and outcome mea-
sures, it is important that the results of potential
performance measures may be adjusted so that differ-
ences observed among providers are attributable to the
care provided rather than to the patients treated.
(4) The measure can be modified by improvements in the
healthcare system. To be useful for facilitating change,
performance measures must be amenable to improve-
ment by motivated providers. This requires that the
potential measure have variability (ie, some systems do
well when judged by the measure, and others do not)
and that evidence supports the feasibility of institutions
or practitioners improving their performance over
time.
(5) The measure is feasible. Quantifying healthcare quality
can be complex and costly. Proposed performance
measures should be sensitive to the logistical and fiscal
implications of assessing quality.
The present report reviews the current state of the art in
quality assessment/improvement and identifies future re-
search priorities for measuring the quality of care in patients
with AMI.
IV. Quantifying the Structure of Care
A. Overview
Structural aspects of AMI care include the systems responsi-
ble for the provision of care (4–7), the material resources on
which those systems depend, and the organizational struc-
tures that guide the interaction of both (3). Patient-care
systems include prehospitalization, emergency department,
inpatient, discharge planning, and outpatient care. Material
resources refer to the personnel (their number, training, and
competence) and equipment available for patient treatment,
whereas organizational systems encompass an institution’s
policies and procedures, reminder systems, disease manage-
ment programs, and quality measurement/improvement infra-
structure. These structural aspects of medical care are impor-
tant determinants of quality (8), and quantifying them can
facilitate quality assessment. In fact, poor outcomes or
processes of care imply flawed systems/structures of care,
and conversely, efforts to improve process and outcome often
lead to improvements in structure. This section describes
methodological considerations for designing structural mea-
sures of healthcare quality and provides several current
examples within different phases of myocardial infarction
(MI) care.
B. Methodological Considerations
Several unique methodological considerations are warranted
when applying the previously described selection principles
to structural performance measures. First, the “outcome” of a
structural measure may be improved adherence with process
measures. For example, an effective system for rapidly
triaging patients with chest pain in the emergency room may
translate into shortened door-to-needle or door-to-balloon
times as emergent reperfusion is provided.
A second consideration in evaluating structural measures is
that the relevant outcome of interest, eg, survival or allevia-
tion of symptoms, may be sufficiently downstream from the
structural component of care that a link to meaningful
outcomes may be technically difficult to establish. In this
case, surrogate outcomes may be relied upon to establish the
first criterion of performance measurement outlined above.
For example, an effective discharge-planning program may
successfully alter patient behavior such that a low-fat diet or
smoking cessation is attained in a high percentage of patients,
yet no significant impact on mortality may be observed.
Despite the absence of a clear link to such a meaningful
patient outcome, the structural performance measure may still
be considered valuable in assessing and improving quality.
Although careful deliberation is needed to endorse such
structural performance measures, the attempt to quantify
structural aspects of care should not be avoided simply
because more direct linkages to outcome are not available. In
fact, structural measures may have their greatest utility when
attributable outcomes are unavailable because of small sam-
ple sizes that preclude the separation of observed outcomes
from random variation. For example, a small, rural hospital
with a rapid triage system that recognizes and transfers AMI
patients presenting with cardiogenic shock for tertiary care
may treat too few patients to appreciate a survival advantage
when compared with similar hospitals that fail to have such
an efficient system.
Finally, the AMI Working Group acknowledges that struc-
tural elements that ensure that the “average” patient is well
treated may not adequately quantify the ability of a system to
handle a unique or particularly ill patient. For example, a
community hospital that implements a process for success-
fully administering aspirin to all AMI patients but does not
have a plan to effectively care for, or transfer, a patient
Figure 1. The spectrum of outcomes in AMI.
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presenting with a ruptured papillary muscle may rarely have
the opportunity for this structural omission to be identified.
To overcome these and other limitations in our present
ability to evaluate structural components of care, the AMI
Working Group recommended that additional research be
directed in this area. Given the absence of clear recommen-
dations in the guidelines for structural measures of quality
and the absence of sufficient research on the development of
structural measures for quantifying quality, the committee
sought to review the literature and suggest several potential
structural measures of quality that could serve as a starting
point for future research.
C. Potential Structural Performance Measures
(1) Prehospital Care
Organized emergency medical response systems are critical
to AMI care. Enhanced 9-1-1 systems can facilitate prompt
medical responses, and trained emergency medical services
personnel with defibrillators can improve survival for patients
with prehospital cardiac arrest. Quality improvement activi-
ties have also been successful at the community level. A
recent program to improve the quality of emergency medical
service systems in Ontario was associated with reduced
response times, improved survival rates, and low annual cost
per life saved among patients suffering out-of-hospital car-
diac arrest (9). Additionally, access to early 12-lead electro-
cardiograms can increase the sensitivity for diagnosing an
AMI (10) and alert emergency rooms to prepare for acute
reperfusion when indicated. Quantifying the availability and
success of such services is needed, but the explicit specifica-
tions of such measures await further research and
clarification.
(2) Emergency Department Care
Both the AHA/ACC guidelines (4–7) and the National Heart
Attack Alert Program (11) recommend the development of
emergency department protocols to promote the rapid iden-
tification and treatment of AMI patients. For example, com-
puterized predictive instruments that provide real-time feed-
back to clinicians (12,13) can reduce delays in the
administration of thrombolytic therapy, although the effect on
outcome is less clear (14). The potential for minimizing the
door-to-needle time by accelerating or avoiding consultations
between emergency physicians and other caregivers before
the administration of therapy has also been documented (15).
Additionally, protocols for identifying low-risk patients can
allow for safe triage to lower-intensity care settings, and the
development of specialized chest pain observation units has
been associated with fewer hospital days and reduced costs
(16,17).
(3) Hospital Management
Many AMI patients fail to receive appropriate treatments
such as aspirin or -blockers, whereas other patients receive
no objective measures of their left ventricular function. Such
errors of omission can be reduced by the use of reminder
systems (18), and structured order forms and checklists have
also been shown to improve drug prescribing (19) and the
delivery of preventive services (20). The use of computer
order-entry systems can reduce medication errors (21,22),
and comprehensive discharge planning can reduce costs and
readmissions for high-risk patients (23,24). “Critical path-
ways” have the potential to improve care (25,26), but effec-
tiveness data confirming their value is lacking (27).
Furthermore, the characteristics of physicians (28,29) and
nurses (30) can impact the quality of AMI care. On average,
cardiologists demonstrate better knowledge of appropriate
AMI care and have better patient outcomes than do generalist
physicians. There is, however, substantial overlap in the
abilities of generalist and specialist physicians (31), and
existing studies are not sufficient to support a policy requiring
that all AMI patients be treated by cardiologists.
The availability of specialized resources such as intra-
aortic balloon counterpulsation and interventional cardiology
may improve outcomes in particularly high-risk patient
groups (32,33). A growing body of literature supports a
volume-outcome relationship for optimal care, at the levels of
both individual practitioners (34,35) and institutions (36–38).
As further evidence clarifies these relationships, the number
of AMI cases treated, at both the provider and institutional
levels, may evolve into structural performance measures. The
implications of this development, especially for rural regions
where the closest hospital may not be a high-volume hospital
will, however, need to be better understood (39).
(4) Discharge Planning
Comprehensive discharge planning, referral to cardiac reha-
bilitation, and patient education are all structural characteris-
tics for which performance measures should be developed.
One such program for patients recovering from an AMI was
associated with improvements in exercise capacity and reduc-
tions in coronary risk factors (40). Nevertheless, the effec-
tiveness of many case or disease management programs has
yet to be tested (40). At present, no such structural measures
have been formally tested with regard to all of the criteria
suggested above, but evolving research may better clarify
how best to quantify these aspects of care.
(5) Outpatient Care
Establishing effective communication between the inpatient
and outpatient settings is essential. AMI may be the initial
manifestation of coronary disease for patients and will trigger
a range of secondary prevention treatments as outlined in
recent guidelines (41–43). A mechanism for quantifying the
success of transferring care between the inpatient and outpa-
tient settings is an important opportunity for improving
subsequent outcomes for which the locus of control is in the
hands of the providers and institution providing AMI care.
Further research to develop such a performance measure is
sorely needed.
(6) Additional Considerations
Although much work is needed to define the performance
measures for quantifying the structure of AMI care, the AMI
Working Group was unanimous that an institutional commit-
ment to measuring and improving AMI performance was
certain to be one such measure. Without a commitment to
understanding present performance, no opportunity for im-
provement is possible. Creating a system to track and im-
prove performance over time as part of Quality Assessment/
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Quality Improvement (QA/QI) is essential. Recent qualitative
work demonstrates that the hospitals that have been most
successful in improving performance have clearly stated
goals for their efforts, administrative support, clinician sup-
port, carefully designed and implemented improvement ini-
tiatives, widespread use of data, and the ability to modify
practice (44). These features fall under the rubric of structure,
and further testing of surveys to quantify the quality of
QA/QI programs will enable their adoption as eventual
performance measures.
D. Past and Future Uses of Structural
Performance Measures
To date, there has been little experience with developing
valid, reliable measures of the systems and structures of care
relevant to the treatment of AMI. The hospital accreditation
surveys conducted by the Joint Commission on Accreditation
of Heathcare Organizations (JCAHO) comprise the most
well-known effort. This survey examines several hospital
departments relevant to AMI care, including the cardiac
catheterization unit; the cardiovascular, medical, and surgical
intensive care units; the emergency, nursing, and pharmacy
departments; and the step-down cardiology unit. Within each
department, these surveys examine various functional do-
mains, including patient assessment and treatment, discharge
planning, managerial organization, and quality improvement.
The review criteria used in these surveys are generic and
generally have not been linked to improvements in specific
aspects of AMI care.
Because of the limited attention given to quantifying the
structure of AMI care, there are substantial variations be-
tween hospitals in the structure and systems used. Although
the absence of valid, reliable measurement tools limits the
utility of structural measures for accreditation or external
reporting, examination of structure can be a critical aspect of
quality improvement activities. Future research is needed to
define performance measures for structural aspects of care in
the setting of AMI treatment. Although current national
efforts, including the Performance Measurement Coordinat-
ing Council (a joint effort of JCAHO, the National Commit-
tee for Quality Assurance, and the American Medical Asso-
ciation) (45) and the ACC/AHA Joint Task Force on
Performance Measures, have not addressed structural perfor-
mance measures, it is hoped and anticipated that such
measures will be adopted and implemented in the future.
V. Quantifying the Process of Care
A. Background
In contrast to the preliminary state of affairs in quantifying
the structure of AMI care, measuring, reporting, and improv-
ing the process of care are well established. Several features
of process measurement led to its growing use and impor-
tance. First, process measures are the most direct application
of clinical trials and the guidelines that interpret these trials.
Second, process measures are often readily quantifiable
actions that occur in sufficient numbers—at least at larger
centers—such that robust estimates of performance are sta-
tistically attainable. Finally, process measures are under the
direct control (and accountability) of the practitioner and
institution providing care.
There is substantial evidence that currently available pro-
cess measurements can improve (27,46,47) and can be
associated with improved patient outcomes (46), and that
“America’s best” hospitals perform these measures more
often than other institutions (48). Despite the potential for
process measures to be valuable tools in quantifying and
improving quality, some hospitals with relatively poor appar-
ent adherence will have excellent outcomes, whereas others
with excellent compliance will have poor outcomes. Al-
though the AMI Working Group acknowledged these limita-
tions, it felt that minimizing variations in the process of
healthcare delivery, where clear evidence defines a link
between established performance measures and meaningful
patient outcomes, could substantially improve the quality of
AMI care.
B. Methodological Considerations
As noted in Section III (Principles for the Selection of Quality
Performance Measures), strong evidence of a clinically mean-
ingful benefit is essential to the choice of process measures,
which usually requires unequivocal results from randomized,
controlled trials. In addition, support of a quality measure by
effectiveness data addressing the generalizability beyond the
population studied in randomized, controlled trials is needed.
Such data are particularly relevant for the elderly, a group that
is chronically underrepresented in randomized controlled
trials (49). Agencies that create and endorse performance
measures generally begin with the guidelines developed by
themselves or by other, national specialty societies. For
example, the practice of the ACC/AHA Task Force on
Performance Measures is to have writing groups use the
ACC/AHA Clinical Guidelines as a basis for selecting poten-
tial processes to measure.
The next steps in performance measurement development
are to define the population of interest, the duration of time
during which care for a patient will be assessed, and opera-
tionalizing the definition of each measure. Specification of
data items is challenging. Data specification must not only
reflect the range and type of data available and the data
elements needed to capture application of the performance
measure (ie, specifying the numerator), but they must also
define those scenarios in which the performance measure was
appropriately not applied (ie, restricting the denominator).
After potential measures are created, field-testing for feasi-
bility is needed. Finally, given that the importance of differ-
ent measures varies by their intended use, a process of
selection and final approval by the entity developing the
performance measures is needed. In the example of the
ACC/AHA Performance Measures, external review by prac-
ticing cardiologists and other specialty groups is elicited, and
then final approval by the ACC’s Board of Governors and the
AHA’s Scientific Advisory and Coordinating Committee is
obtained before endorsement.
Once measures are constructed, their appropriate applica-
tion must also be addressed. For example, when one intends
to use a process measure to compare the performance of
different providers (eg, individual practitioners or hospitals)
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or groups of providers (eg, hospitals or regions of hospitals),
a sufficiently large number of potential candidates for the
process measure must be available so that statistically mean-
ingful comparisons can be performed. Thus, statewide com-
parisons are likely to be more meaningful than comparisons
at the hospital or provider level.
At the hospital level, it is important to have clarity about
the purpose of performance measurement. Although publicly
reported comparisons may not be appropriate (because of
limited numbers of cases limiting the accuracy of estimated
rates, the quality/accuracy of chart abstraction, etc), bench-
marking internal performance against achievable benchmarks
of care offers a unique opportunity to identify areas for
improvement (50). Furthermore, the greater the frequency
with which a performance measure can be applied, the greater
the opportunity to perform rapid cycle efforts to improve
performance. The minimum proportion of AMI cases to be
eligible for a given care process so as to effectively conduct
performance measurement/improvement has not yet been
determined. The Working Group estimated that the minimal
number of eligible cases is likely to be between 10% and
20%, according to the intended purpose for quantifying
performance.
Several important considerations are relevant with regard
to the acquisition of data for performance measurement.
Clinical information contained within administrative data sets
(eg, billing data) is not, in general, sufficiently rich to allow
valid conclusions about the quality process to be drawn. This
is likely to change dramatically over time as the use of
electronic medical records increases. Currently, for inpatient
processes of care such as AMI, the medical record must be
reviewed to determine the appropriateness of a given process
measure for a given patient (ie, important contraindications
for the therapy were not present) and whether the process of
care was applied. Structured medical record review can be
carried out internally (by the institution where the medical
record resides) or externally (by an entity specially commis-
sioned to undertake such review). For internal review the
responsibility for finding the details necessary to determine
whether the process of care was correctly performed rests
with the provider, as does the resource burden for abstraction.
Inclusion bias, nonuniformity, and limited reliability of re-
porting may be present, and without audits, the magnitude of
this potential problem cannot be known. This is the case, for
example, for those providers who participate in the National
Registry of Myocardial Infarction quality performance mea-
surement initiative or the ACC’s National Cardiovascular
Database Registry.
In contrast to internal review, external record reviews
provide more reliable measurements (51), but completeness is
always subject to the lack of standards and the variability of
medical record documentation. In addition, the burden of
abstraction is shifted from the provider to the measurer. For
quality performance measurement of AMI processes of care,
both methods of record abstraction have been used (see
below). When external and internal record reviews are used
independently to determine quality performance, however,
preliminary evidence suggests that the results are comparable
(52).
C. Potential Performance Measures for the
Process of Care
Multiple agencies are currently engaged in performance
measurement. Table 1 outlines currently used performance
measures for quantifying quality in the provision of AMI
care. These measures have been determined to adhere to the
principles outlined above and have been used to quantify and
compare quality among different regions of the country as
part of public reporting and among different hospitals as part
of local quality improvement efforts. The exact specifications
TABLE 1. Current Process-of-Care Quality Performance Measures for AMI*
Quality Performance Measure
Evidence for
Process–Outcome
Link†
Measurement Reliability
and Validity
Measurement
Burden
Estimated
Compliance‡
Barriers to Change;
Change Achieved
Timely reperfusion A Good Moderately
high
30% within
30 minutes
High, but have been
successfully addressed
Early aspirin administration A Good Moderate 85% Low to moderate;
change achieved
Early -blocker administration A Good Moderate 69% Moderately high;
change achieved
Smoking cessation counseling C (for outcome of
smoking cessation)
Probably adequate Moderate 43% Moderate; change
achieved
ACE inhibitor for depressed left
ventricular ejection fraction
B Good Moderate 74% Moderate; change
achieved
-Blocker at discharge A Good Moderate 79% Moderate to high;
change achieved
Aspirin at discharge A Good Moderate 86% Low; change achieved
*These measures have not been officially endorsed by the AHA or ACC.
†A indicates randomized controlled trials plus effectiveness evidence beyond RCT populations; B, randomized controlled trials without effectiveness evidence; C,
other evidence supporting process of care; and D, guideline recommendation only.
‡Data for estimated compliance from reference 53.
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by which different accrediting agencies apply these measures
may differ, although recent efforts are toward consolidation
of such specifications. Table 1 also estimates current compli-
ance (levels100% reflect the opportunity for improvement)
and barriers to such improvement (53). Because the process
of performance development and measurement is dynamic,
several measures are currently under consideration for future
use. These are briefly outlined in Table 2.
D. Past and Future Uses of Process
Performance Measures
Multiple organizations are now quantifying performance in
the care of AMI patients. The efforts of these organizations
differ in their goals, the perspective of their analyses, and the
specifications of their measures. Accordingly, the scope,
purpose, and approach of different organizations are changing
rapidly. Although a complete description of current perfor-
mance measures is beyond the scope of the present statement,
Table 3 describes the most active organizations in quantifying
healthcare quality for AMI and provides current web site
references so that interested readers can acquaint themselves
with each organization’s most current efforts.
VI. Outcome Measures
A. Background
A broad range of patient outcomes may be affected by the
quality of care delivered to patients with AMI (Figure). These
can be classified into clinical events (eg, death, heart failure,
recurrent MI), health status (eg, symptoms, functional status,
quality of life), patient satisfaction, and healthcare costs. The
AMI Working Group did not consider physiological mea-
sures (eg, cholesterol levels, blood sugar control in diabetic
patients, or blood pressure control in hypertensive patients) as
patient outcomes. Although such surrogate measures may be
effective tools for monitoring the success of important pro-
cesses of care, they are relatively silent from the patient’s
perspective. The goal in treating these physiological states is
to prevent the mortality and impaired quality of life that are
the consequences of such pathophysiological abnormalities.
B. Methodological Considerations
Three major methodological issues were considered by the
AMI Working Group: the time period during which the
outcome was assessed, the impact of patient characteristics on
outcome, and the statistical robustness of outcome measures.
(1) Assessment Time Period
Defining the appropriate time period during which outcomes
should be collected is challenging. Considerations such as the
ease of data collection and the attribution of responsibility to
a particular provider favor collecting outcomes over a short
time period, such as 30 days after hospital admission. Some
may opt to use the in-hospital stay because of convenience,
but that is a nonstandardized period of assessment. In any
case, the potentially modifiable component of short-term
outcomes may be small, particularly for very elderly patients
or patients with significant comorbidity. More importantly,
the full impact of the structures and processes of care, from
the emergency medical response through acute reperfusion to
TABLE 2. Proposed Process-of-Care AMI Performance Measures of Quality*
Quality Performance Measure
Evidence for
Process–Outcome Link†
Measurement Reliability and
Validity
Measurement
Burden
Estimated
Compliance‡ Barriers to Change
Administration of reperfusion A Concerns about reliability and
validity
High 67% (any
reperfusion)
High, but have been
successfully addressed
Cholesterol measurement before or after
discharge
C Probably good when obtained
from medical record; lab
database reliability unknown
Moderate Unknown Moderate
Cholesterol management at or after
discharge
B Probably good when obtained
from medical record;
pharmacy database reliability
unknown
Moderate Unknown Moderate to high
Avoidance of calcium channel blocker
for patients with contraindication
C Good Moderate 82% Opportunity for
improvement limited
Counseling about risk factors other than
smoking
D Concerns about
documentation variability and
completeness
Moderate Unknown Moderate
Referral for cardiac rehabilitation
program
C Unknown Moderate to
high
Unknown Moderate to high
Administration of influenza vaccines D Unknown Moderate to
high
Unknown Moderate to high
Management of complications of AMI
(eg, shock, heart failure)
C Good for occurrence,
unknown for appropriateness
High Unknown High
*These measures have not been officially endorsed by the AHA or ACC.
†A indicates randomized controlled trials plus effectiveness evidence beyond randomized controlled trial populations; B, randomized controlled trials without
effectiveness evidence; C, other evidence supporting process of care; and D, guideline recommendation only.
‡Data for estimated compliance from reference 53.
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long-term secondary prevention, may not be manifest until
years after the event. Finally, the transition between inpatient
and outpatient care (54–56) and the application of secondary
prevention measures may be at least as important as many
acute care decisions (57).
Despite these limitations of short-term outcomes, it was
also recognized that assessing quality of care from a longer-
term prospective is controversial, particularly because a
longer timeframe significantly reflects outpatient treatment
decisions that may not be under the direct control of the acute
healthcare provider. The AMI Working Group felt, however,
that even when initial in-hospital providers are not in charge
of care after discharge, they do assume a responsibility for
appropriate communication to patients’ primary care physi-
cians. Furthermore, if a hospital is identified as having poor
long-term patient outcomes, then internal reflection can help
identify whether this is due to inpatient or outpatient pro-
cesses of care. Ultimately, this should trigger quality im-
provement in both the structure and processes of care that can
lead to better outcomes. When weighing these considerations,
the AMI Working Group felt that although measurement of
in-hospital or 30-day outcomes provided some opportunity to
improve care, greater emphasis on longer-term outcomes
(preferably at 1 year) would most effectively facilitate more
substantive improvements in quality.
(2) Impact of Patient, Rather Than Provider,
Characteristics on Patient Outcomes
Patients’ outcomes after AMI are influenced by a host of
patient-specific factors, including demographics (eg, age,
sex), disease severity (eg, type of MI, underlying coronary
anatomy, ventricular function before and after the MI),
comorbid illness (eg, diabetes, chronic obstructive pulmonary
disease), treatment factors, and chance. The goal in quality
assessment is to distinguish the modifiable, provider-related
component from these other confounding clinical factors. The
statistical methodology needed for appropriately risk-
adjusting provider outcome comparisons has been the subject
of several recent reviews; it requires building multivariate
models to weight the most important patient-specific factors
so that deviations in outcome can be attributed to the care
provided rather than the patients cared for (58,59).
(3) Impact of Chance on Patient Outcomes
It was, however, recognized by the Working Group that even
if perfect risk-adjustment models were available, chance
could likely obscure true differences in quality among pro-
viders. This randomness in biology makes accurate measure-
ment of healthcare quality by using outcomes challenging
(60). The compensating factor for random occurrences is the
number of outcomes observed. As this increases, the relative
influence of chance on an outcome measure diminishes. With
regard to MI care, however, the number of patients treated
(and number of events seen) by most hospitals is often
limited, making accurate, reliable, and precise quality differ-
entiation challenging (61). Despite these limitations, the AMI
Working Group felt that efforts to measure and report, at least
internally, long-term outcomes could create important oppor-
tunities for self-analysis and subsequent quality improve-
ment. Because of sample size and risk-adjustment limitations,
however, mortality may not be appropriate for public
reporting.
C. Potential Performance Measures for Outcomes
(1) Mortality
Survival is clearly a meaningful end point for patients and
society. In-hospital survival rates are readily assessed, and
postdischarge vital status can be obtained by querying the
National Death Index and/or through direct patient contact.
Yet the complexity of creating linkages to these data sources
requires resources that may exceed the capacity of smaller
hospital and provider systems. Furthermore, the validity of
this outcome is compromised by current limitations in risk
adjustment. Ongoing research is contributing substantial in-
sight into the appropriate models, but even the best current
models are unable to attain C-statistics (a coarse index of the
TABLE 3. Organizations Involved in the Measurement of Quality in AMI
Organization Web Site* Perspective Most Relevant Activity
Centers for Medicare & Medicaid Services
(formerly the Health Care Financing
Administration)
www.cms.gov Payer National Heart Care Project
Joint Commission on the Accreditation of
Healthcare Organizations
www.jcaho.org Hospital ORYX Initiatives
American Medical Association www.ama-assn.org Physician Physician Consortium for Quality Improvement
National Quality Forum www.qualityforum.org Payer Hospital Performance Measures Project
American Heart Association www.americanheart.org Hospital Get with the Guidelines
ACC/AHA Task Force on Performance Measures
American College of Cardiology www.acc.org Physician Guidelines Applied in Practice
ACC/AHA Task Force on Performance Measures
Veterans Affairs Health System www.va.gov Hospital Ischemic Heart Disease Quality Enhancement
Research Initiative (IHD QUERI)
National Committee for Quality Assurance www.ncqa.org Health Plan Healthplan Employers Data and Information Set
(HEDIS)
*Web addresses shown were verified on February 18, 2003.
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discrimination of such models) that exceed 0.80 (range, 0.5 to
1.0) (62–64). As noted in the preceding section, even if
perfect risk adjustment methodologies were available, the
limited yearly hospital volume of AMI patients (and the
relatively low event rate) makes identification of superior and
inferior outliers difficult. In fact, statistical simulations dem-
onstrate that a quality assessment scheme based on hospital
mortality outcomes may have a predictive error rate ap-
proaching 50% (61). Thus, mortality outcomes may reason-
ably correlate with the quality of care at system or regional
levels but are limited when the number of events is lower,
such as at the hospital or individual provider level. Given the
methodological limitations noted, the AMI Working Group
concluded that mortality (at 30 days and 1 year) could be
useful for internal quality improvement but that the imper-
fection of existing risk-adjustment techniques, the potential
for nonmodifiable mortality (especially in high-risk groups),
statistical instability in small samples, and the play of chance
conspire to make mortality end points inappropriate for
public reporting, especially for comparing individual
providers.
(2) Repeat Hospitalizations
In addition to mortality, repeat hospitalization could be an
appealing outcome measure of disease progression (Figure)
given its relatively easy quantification, the frequency of its
occurrence, and its meaningfulness to patients and healthcare
systems (due to increased costs). Concerns about using this
outcome as a marker of healthcare quality, however, include
the potential to underestimate significant event rates because
not all significant events result in a hospitalization. Further-
more, hospitalization rates may be strongly associated with
bed availability, thus undermining the interpretation of this
outcome (65). In addition, some readmissions may be
planned and therefore not necessarily representative of a
negative outcome. Combining hospitalization with mortality,
because patients who die during the follow-up period are no
longer subject to readmission, may mitigate the first of these
concerns. Deaths contribute relatively little to this combined
outcome, however; thus, the import of this outcome is more
diluted than its description would imply. As noted for
mortality, however, few data are available to create robust
risk-adjustment models for readmission, and thus, patients’
characteristics combined with chance may undermine the
usefulness of readmissions in reflecting the quality of care
provided.
Given these potential benefits and challenges of quantify-
ing readmission, the Working Group recommends that rehos-
pitalization after AMI be examined when the group examin-
ing this outcome can link the analysis to a meaningful quality
improvement process. If hospitalizations are to be included in
an outcomes assessment, then a window of at least 3 to 6
months after the index admission is recommended. This
quality metric will assure that AMI hospital stays are not
shortened to the point of harm (66) and that appropriate
longitudinal care plans are established for patients. Although
it may eventually be possible to judge healthcare plans on
longer-term cardiac event rates (measured in years) as a
measure of successful secondary prevention care, given the
present lack of information systems and risk-assessment
schemes to measure and evaluate these end points, these
recommendations remain a goal rather than a reality, and
external reporting of such outcomes data is not advocated.
(3) Health Status
Health status includes the symptoms, function, and quality of
life of patients after their acute AMI care. These outcomes are
clearly meaningful to patients and society. Several mecha-
nisms of quantifying health status are available and include
physician-assigned (eg, the Canadian Cardiovascular Society
classification) (67) and patient-centered measures (eg, the
Seattle Angina Questionnaire) (68,69). Yet these assessments
can be resource intensive and difficult to perform in routine
practice. Furthermore, limited research has been directed
toward developing risk-adjustment models for these out-
comes, and until this methodological work is done, separating
patient characteristics from the quality of treatment cannot be
accomplished. Although the AMI Working Group clearly
recognized the benefits of quantifying patients’ perspectives
of their disease status and noted that such insights could be
invaluable to healthcare systems seeking to maximize the
quality of their treatment of patients with coronary disease,
current challenges in collection and analysis preclude recom-
mending health status as a performance measure for external
reporting. It is, however, one of the most important research
priorities for advancing the field of quality assessment and
improvement.
(4) Costs
Costs are a highly relevant outcome from the perspective of
providers and society. However, from the perspective of
patients in the current American healthcare system, costs are
largely hidden. The AMI Working Group did not feel that
costs were an appropriate metric with which to assess the
quality of health care at this time, although it may have value
for internal quality improvement efforts intended to improve
the efficiency of care.
(5) Patient Satisfaction
Although highly relevant to healthcare systems that seek to
retain patients, patients’ satisfaction with care is of unclear
import to patients themselves and to society. Much work is
needed to better measure patient satisfaction. Although
progress is being made in generic assessments of patient
satisfaction (eg, Consumer Assessment of Health Plans
[CAHPS]), only the treatment satisfaction scale of the Seattle
Angina Questionnaire quantifies this domain in a disease-
specific fashion. More work is needed to better understand
how to validly capture patients’ satisfaction with their care
for an AMI. In addition, few risk-adjustment models are
available (70), and the highly skewed nature of data creates
significant methodological challenges to the use and report-
ing of patient satisfaction data. Hence, although patient
satisfaction is clearly important to the reputation of a provider
or an institution within a community, it is not sufficiently
mature methodologically or sufficiently meaningful as an
outcome to be endorsed by the AMI Working Group as a
measure of quality.
1660 Spertus et al. JACC Vol. 41, No. 9, 2003
Quantifying Quality of Care for AMI May 7, 2003:1653–63
D. Past and Future Uses of Outcome
Performance Measures
Few efforts at using outcomes in the quantification of
healthcare quality in the treatment of AMI are available for
review. Furthermore, the challenges in data collection, risk-
adjustment, and interpretation make it unlikely that major
accrediting bodies will endorse outcome measures in the near
future. However, the AMI Working Group felt that this is one
of the most important opportunities for future research and
that the development of improved information systems is
likely to create important opportunities for collecting such
outcomes in the future. Furthermore, as risk-adjusted meth-
ods for providing outcomes data to providers are developed,
they are likely to provide valuable insights into the need for
more careful evaluation of current processes and structures of
care that, in turn, will lead to improved outcomes over time.
VII. Recommendations for Future Research
The demand for quality assessment and improvement in
health care has quickly outstripped medicine’s knowledge of
how to meet this demand with methodologically rigorous
techniques that cover the full spectrum of healthcare delivery,
structure, process, and outcomes. Accordingly, the Working
Group identified several important research priorities. These
include:
 A greater focus on measuring and interpreting outcomes,
particularly longer-term outcomes
● The development of new and improved risk-
adjustment techniques for a variety of outcomes,
including mortality, health status, hospital admis-
sions, and costs
● Expanded research into the transition of care from the
inpatient to the outpatient settings
● Increased efforts toward the efficient collection and
attribution of long-term outcomes
 More research to translate the results of analyses into
improvements in healthcare delivery, including:
● Recognizing and acting on opportunities to improve
care
● Examining models of increased accountability within
an individual organization
● Evaluation of alternative optimal performance feed-
back methodologies
 More research into measuring and improving the struc-
tures of care, including:
● How to quantify the links between structure, process,
and outcomes
● Examining the interaction of different systems of care
and how to optimize changes in current systems in the
most nimble and effective manner
● Learning how to quantify the quality of transitions
from the inpatient to the outpatient condition
 Greater clarity of the purpose of performance measures
so that those who develop them are explicit about their
purpose as the properties of the measures may change
 Greater coordination among those designing perfor-
mance measurement systems with particular attention on
how to minimize the financial burden on those being
measured to participate in meaningful quality improve-
ment efforts
 Greater attention by those creating clinical practice
guidelines to the need for eventually creating perfor-
mance measures so that those recommendations that are
most important for improving patient outcomes are
highlighted and that the inclusion/exclusion criteria of
appropriate patients are clearly delineated
 More research to quantify appropriateness measures for
diagnostic and therapeutic procedures after AMI
 More work identifying how to measure and improve the
incorporation of patient preferences into the process of
medical decision-making (Although current efforts are
aimed at decreasing the variability of treatment from
established guidelines, the variability in care should be
wide when this variability is due to patient preferences.)
Summary and Conclusions
Quality performance measurement and improvement have
been in place for AMI for several years, particularly within
the process-of-care domain. Through the use and analysis of
these measures, physicians, hospitals, oversight agencies,
researchers, and consumers have learned about how quality
care can be measured, about variability in care, and about the
effectiveness of current practice patterns. Most importantly,
quality performance measurement for AMI has provided a
focus and direction for those devoted to improving care.
Despite evidence of early success from these efforts, there
remains substantial additional work yet to do. The Working
Group believes that if the true potential for American health
care is to be realized, substantial national funding and support
for strengthening the scientific foundation of quality mea-
surement and improvement are needed for our country to
effectively translate the accumulating evidence of medicine
into routine clinical practice.
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